论文部分内容阅读
目的探讨人尿激肽原酶(尤瑞克林)治疗急性脑梗死的疗效及安全性。方法采用丹参+奥扎格雷+人尿激肽原酶(治疗组)及丹参+奥扎格雷(对照组)治疗急性脑梗死患者,使用NIHSS和mRS评价治疗前后神经功能缺损程度及临床疗效。结果治疗后治疗组患者NIHSS和mRS评分均优于对照组,两者比较差异有统计学意义(P<0.05),临床疗效总有效率达85%,无明显不良反应。结论尤瑞克林治疗急性脑梗死安全、有效,不良反应少。
Objective To investigate the efficacy and safety of human urokinase (urelin) in the treatment of acute cerebral infarction. Methods The patients with acute cerebral infarction were treated with Salviae Miltiorrhizae + Ozagrel + human Urokinase (treatment group) and Salviae + Ozagrel (control group), and the NIHSS and mRS were used to evaluate the degree of neurological deficits and clinical efficacy before and after treatment. Results After treatment, the scores of NIHSS and mRS in the treatment group were better than those in the control group. The difference between the two groups was statistically significant (P <0.05). The total effective rate of the clinical effect was 85%, with no obvious adverse reactions. Conclusion Erilecin treatment of acute cerebral infarction is safe and effective, with fewer adverse reactions.